Royal London Asset Management Ltd. Buys 1,152 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Royal London Asset Management Ltd. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,675 shares of the biopharmaceutical company's stock after purchasing an additional 1,152 shares during the quarter. Royal London Asset Management Ltd.'s holdings in Regeneron Pharmaceuticals were worth $45,913,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of the business. Brown Lisle Cummings Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company's stock worth $68,000 after acquiring an additional 10 shares during the last quarter. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Adirondack Trust Co. increased its stake in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after buying an additional 10 shares during the period. UMB Bank n.a. increased its stake in Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after buying an additional 10 shares during the period. Finally, Western Financial Corp CA increased its stake in Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company's stock worth $1,912,000 after buying an additional 12 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $10.10 during trading hours on Friday, reaching $778.00. 813,640 shares of the company's stock traded hands, compared to its average volume of 547,914. The business's fifty day simple moving average is $882.14 and its two-hundred day simple moving average is $1,013.01. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The firm has a market capitalization of $85.49 billion, a price-to-earnings ratio of 19.25, a P/E/G ratio of 2.89 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. JPMorgan Chase & Co. cut their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating on the stock in a research report on Thursday, October 24th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 target price on the stock. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Finally, Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $1,107.29.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.